Anixa Biosciences (ANIX) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed Anixa Biosciences (ANIX) over the past year, gaining 4.9% versus a loss of 34.5%. Over five years, ANIX leads with a -33.7% price change compared with -93.8% for PMVP. PMV Pharmaceuticals is the larger company by market cap ($112.5 million vs $101.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | PMVP |
|---|---|---|
| Share price | $2.91 | $1.49 |
| Market cap | $101.16M | $112.51M |
| 1-day change | -1.36% | -0.67% |
| YTD return | -6.73% | +19.20% |
| 1-year return | -34.46% | +4.93% |
| 5-year return | -33.71% | -93.78% |
| EPS (TTM) | $-0.32 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $1.91 |
| 52-week low | $2.32 | $1.02 |
| Distance from 52-week high | -46.70% | -21.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +235.05% | +181.88% |
| Average volume | 302.95K | 661.39K |
| Shares outstanding | 34.76M | 75.51M |
| Employees | 4 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed ANIX by 39.4 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
ANIX vs PMVP FAQ
Which is bigger, Anixa Biosciences or PMV Pharmaceuticals?
PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $112.51M compared with $101.16M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -34.46% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.